Biosimilar Use in Breast Cancer Treatment: A National Survey of Brazilian Oncologists' Opinions, Practices, and Concerns

Biosimilar Use in Breast Cancer Treatment: A National Survey of Brazilian Oncologists' Opinions, Practices, and Concerns

PURPOSEBreast cancer is the most common malignancy in Brazilian women, with 66,280 new cases in 2020 (with 20% overexpressing human epidermal growth factor receptor 2 [HER2]). The trastuzumab biosimilar was the first oncology biosimilar approved in Brazil for HER2-positive breast cancer treatment. T...

Full description

Bibliographic Details
Main Authors: Heloísa M. Resende, Leandro Ladislau, Ana Carolina F. Cardoso, Juliana Dinéia P. Brandão, Biazi R. Assis, Paola Cardoso, Pedro Henrique A. Marassi, Vivienne Castilho
Format: Article
Language:English
Published: American Society of Clinical Oncology 2021-12-01
Series:JCO Global Oncology
Online Access:https://ascopubs.org/doi/10.1200/GO.20.00649

Internet

https://ascopubs.org/doi/10.1200/GO.20.00649

Similar Items